Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This study tests a new investigational drug called C6 Ceramide NanoLiposome (CNL) in adults with acute myeloid leukemia (AML) — a type of blood cancer — that has come back after treatment or did not respond to prior treatment. **You may be eligible if:** - You are 18 or older - You have AML that has relapsed (came back) or is refractory (did not respond to prior treatment) - Your overall health and organ function (kidneys, liver, heart) are adequate - Your white blood cell count is below a certain threshold **You may NOT be eligible if:** - You have uncontrolled serious illness (heart failure, unstable heart conditions, severe psychiatric illness) - You are currently in another clinical trial or took an investigational drug within the past week - You are pregnant or breastfeeding - You had another cancer within the past 12 months (with some exceptions) - You have acute promyelocytic leukemia or AML with central nervous system involvement - You have an active HIV, hepatitis B, or hepatitis C infection - You recently had a stem cell transplant with active graft-versus-host disease Talk to your doctor to see if this trial is right for you.